Sinovac Biotech - Stock Price History | SVA

Historical daily share price chart and data for Sinovac Biotech since 2021 adjusted for splits. The latest closing stock price for Sinovac Biotech as of February 22, 2019 is 6.47.
  • The all-time high Sinovac Biotech stock closing price was 10.46 on September 01, 2009.
  • The Sinovac Biotech 52-week high stock price is 0.00, which is -100% above the current share price.
  • The Sinovac Biotech 52-week low stock price is 0.00, which is 100% below the current share price.
  • The average Sinovac Biotech stock price for the last 52 weeks is NaN.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Sinovac Biotech Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 6.5734 6.9800 7.0300 6.3300 6.4700 -6.77%
2018 7.6533 8.0200 8.6800 5.7300 6.9400 -11.93%
2017 6.3970 5.9000 8.0700 4.6400 7.8800 33.56%
2016 6.0072 5.5700 7.1200 4.4900 5.9000 3.15%
2015 5.2257 5.3000 6.1800 4.7000 5.7200 9.37%
2014 5.7797 6.0600 8.0700 4.5700 5.2300 -14.54%
2013 4.4963 3.0700 6.4200 3.0700 6.1200 94.90%
2012 2.2995 2.2800 3.4600 1.6600 3.1400 42.73%
2011 3.2479 4.5700 4.8200 1.9400 2.2000 -51.33%
2010 4.9890 6.5500 7.5100 3.6600 4.5200 -28.59%
2009 4.4728 1.5900 10.4600 1.0400 6.3300 358.70%
2008 3.1565 5.0400 5.1800 0.8500 1.3800 -73.05%
2007 3.5464 2.5000 6.7500 2.3000 5.1200 120.69%
2006 3.3226 3.9500 5.1100 1.9500 2.3200 -42.14%
2005 3.5574 3.5300 7.6400 1.6800 4.0100 12.01%
2004 3.7156 1.7200 6.8500 1.7200 3.5800 103.41%
2003 1.5739 0.8200 1.8000 0.8200 1.7600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.642B $0.511B
Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, `SARS`, and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29